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Introduction 
Coronary angioplasty is the most frequent iiivasive 
treatment for obstructive coronary artery disease. In the 
majority of patientu, this treatment relieves the patient’? 
symptonis. However, roughly one-third of these patients 
develop restenosis following angioplasty. This restenosis 
is characterized by an abnormal proliferation of sniooth 
muscle cells in  the blood vessel wall and is called 
coronary restenosis (CK). CR reduces the effect of 
coronary angioplasty on the patient’s symptoms, some- 
times leaving the patient in a worse condition than 
before. There are several parallels between accelerated 
graft arteriosclerosis (AGA) seen in heart transplant 
recipients (also known as allograft vasculopathy) and 
CK [I]. Both lesions develop rapidly and both are 
characterized by an exuberant proliferation of smooth 
muscle cells. 
The same mechanisms underlying the develop- 
ment of CI1 and AGA may also play a role in the 
developnient of atherosclerosis. A better understanding 
of the process of atherosclerosis could lead to new, more 
effective therapeutic agents for the treatment of the 
primary cause of death in the Western world. 
Epidemiologic studies have shown that human 
cytomegalovirus (HCMV) infection may promote the 
developnient of both CR and AGA [I]. HCMV may 
also be involved in the pathogenesis of atherosclerosis. 
The precise role of HCMV in these processes is, 
however, unclear, as are the mechanisms by which 
HCMV promotes these processes. Recently it has been 
suggested that interactions between HCMV and the 
p53 tunior suppressor gene product could stimulate 
smooth muscle cells to proliferate, leading to CK [2]. 
This hypothesis is intruiging, since it links arterial 
disease with cell cycle regulation and an infectious 
disease. This contribution will review the basic features 
of the p53 tumor suppressor gene and the possible role 
of p53-HCMV interactions in the development of 
atherosclerosis. 
The p53 tumor suppressor gene 
The p53 gene is a tumor suppressor gene located on 
chromosome 17p. It  encodes a 53-kDa nuclear protein 
called p53. The main function of wild-type p53 is 
preventing the cell from replicating if the DNA is 
damaged. Cell division with damaged DNA would lead 
to fixation of the damage in the genotype of the cell. 
This would increase the sensitivity of the cell to further 
DNA damage arid it is considered an important step 
in carcinogenesis. Because of its function, p53 is 
nicknamed the ‘guardian of the genome’. p53 functions 
through at least three diffent molecular mechanisms 131. 
First of all, p53 serves as a checkpoint in the cell 
cycle (Figure 1). At  the transition from the <;1 ph,isc 
to the S phase,jiist prior to synthesis ofLINA, p53 stops 
cell cycle progression if the DNA is damaged. This cell 
cycle arrest is primarily mediated by a protein called 
WAF1 (or p21), for which p53 acts as a transcription 
factor. The slowing of cell cycle progression allows 
darnaged DNA to be repaired before it is duplicated. 
Second, in addition to increasing the time available for 
TINA repair, p53 also stimulates DNA repair directly 
by interacting with several cellular proteins (e.g. PCNA 
and GADD45) (Figure 1). Finally, if LINA damage is 
severe, p53 pushes the cell into programmed cell death 
(or apoptosis), thereby preventing duplication of the 
damaged DNA. The main mediators acting with p53 
in  this process are proteins called 13~12 and Bax (Figure 
In nornial cells, two alleles of the p53 gene are 
present, a paternal and a maternal copy. The presence 
of one nornial allele is sufficient for p53 to exert itc 
protective function. Thus, a t  the molecular genetic 
level, two distinct events are required to lose both 
alleles, resulting in functional loss of p53 [3].  The most  
coinnion way for p53 function to be inactivated in 
tumors is to lose the function of one allele by a 
mutation and to lose the second allele by deletion. 
In addition to molecular genetic alterations, 
another mechanism by which p53 fuiiction can be lost 
is at the protein level. A variety of proteins have been 
identified which bind to the p53 protein and impair its 
function. Examples include the large T-antigen of 
SV40 and E6 of HPV. These interactions can  also 
stabilize the wild-type p53 protein, which therefore 
also becomes detectable by iIriniunohistocheriiica1 
staining. 
1 )  ~31. 
p53 and HCMV in atherosclerotic vascular disease 
Epidemiologic studies have demonstrated an associa- 
tion between high levels of antibodies to HCMV and 
atherosclerotic vascular disease. There is little doubt 
that HCMV does have a predilection for vascular tissue. 
It is consistently found at these sites in asymptoniatic 
accident victims, whereas other ubiquitous viruses are 
not. The exact nature of HCMV infection in the cells 
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Figure 1 p53 and cell cycle regulation 
of the arterial wall is a critical issue that is far from 
resolved; however, it has been suggested that latent 
HCMV infection, limited to the expression of a subset 
of immediate-early (IE) viral genes, appears to be 
important in AGA. 
Recently, it has been suggested that CR is mediated 
by an interaction between HCMV and the p53 gene 
product [2]. This hypothesis is based on the observation 
that wild-type p53 protein is overexpressed in CR 
lesions. Remarkably, this overexpression correlates with 
the presence of HCMV-IE84. Based on these obser- 
vations, Spier et al have hypothesized that injury to the 
coronary artery wall at the time of angioplasty activates 
latent HCMV in the cells of the arterial wall. This leads 
to an increased expression of HCMV-IE84, which 
binds to and inactivates the p53 gene product. Loss of 
the regulatory function of p53 on the cell cycle results 
in a selective growth advantage for the infected smooth 
muscle cells, leading to uncontrolled proliferation and 
thus CR. 
Although HCMV infection is a major clinical risk 
factor for AGA, we were not able to demonstrate the 
accumulation of p53 protein in the coronary arteries 
of HCMV-positive transplant patients suffering from 
AGA. Furthermore, the expression of WAFl, a protein 
for which p53 acts as apnscription factor, was normal 
in these coronary arteries, suggesting the presence of a 
functional p53 protein [l]. Thus, we were not able to 
confirm the postulated causal role of HCMV infection 
in AGA through interaction with the p53 protein [2]. 
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Concluding remarks 
C R  and AGA are clinically important processes in 
which coronary artery lumina can rapidly narrow. 
The etiology of these processes is not known, but both 
processes have been epidemiologically linked to HCMV 
infection. Further investigation is needed to define the 
role of interactions between HCMV and p53 in both 
of these processes. 
The demonstration that the HCMV gene product 
can inactivate the p53 gene product suggests that a 
better understanding of CR and AGA might be 
achieved if we consider these processes a form of 
benign neoplasia. This concept fits very well with loss 
of regulatory function on the cell cycle by inactivation 
of the p53 protein. A causative role for HCMV in this 
process would provide us with other-and perhaps 
better-therapeutic modalities for this disease, which 
would have a major clinical impact. 
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Broad- and narrow-spectrum antibiotics: an unhelpful 
categorization 
Clin Mirrobiol Infect 1997; 3: 395-396 
The expression ‘broad-spectrum antibiotic’ was used 
in the mid-l950s, when the bacterial spectrum of 
chloramphenicol and the first tetracyclines could be 
strikingly opposed to the narrow spectrum of activities 
of penicillin G, and streptomycin. In the 1960s, amino- 
penicillins, then ureidopenicillins, became the broad- 
spectrum penicillins in comparison with penicillin G. 
Until then, the quality of being broad spectrum or 
narrow spectrum was given to an antibiotic only when 
referring to a comparator. Later, the reference to a 
comparator was omitted, and broad and narrow lost 
their relativities and became independent character- 
istics of a compound, used with different meaning and 
often improperly. 
Never, to my knowledge, was any effort made to 
define those words. O n  what segment(s) of the range 
of bacterial species (Gram-positive cocci and bacilli, 
Enterobacteriaceae, non-fermentative Gram-negative 
rods, anaerobes, intracellular pathogens) is the classifica- 
tion as broad- or narrow-spectrum antibiotics to be 
based? O n  the narrow side, some compounds are 
narrower than others (e.g. macrolides versus metro- 
nidazole), while on the broad side, many antibiotics are 
narrower than the very broad ones (e.g. tetracyclines are 
broader than tazocillin, which is broader than cephalo- 
sporins, etc.). I will not attempt now to propose any 
definition of what is narrow and what is broad. I would 
like only to draw attention to the overuse of such 
ambiguous labels for different and even contradictory 
purposes. In my experience, this consideration justifies 
ceasing to use them. 
Broad spectrum as an expression of greater thera- 
peutic security has mainly been used by the pharma- 
ceutical industry. Most antibiotics are prescribed 
empirically on a presumptive diagnosis. This implies 
that several bacterial species are possible causes of the 
disease. It is correct that a broad-spectrum antibiotic 
may offer a better chance of covering the causative 
microorganisms. In the same way, a broad-spectrum 
agent is indicated in a large number of clinical situations. 
Recently, the trend in the pharmaceutical industry 
has been to replace the concept of broad-spectrum 
agents by organ- or system-targeted agents. The 
empirical choice of an antibiotic is determined by 
the organ or system in which the infection is located. 
This approach integrates the pharmacokinetic pro- 
perties and the activity against the more frequent 
bacteria encountered in the particular location of 
the infection. Antibiotics suitable for urinary tract 
infections, respiratory infections, digestive tract iri- 
fections, etc., have been developed. Progress can be 
expected from new compounds, and improved clinical 
approaches for the therapeutic decisions. 
The idea of broad-spectrum agents as broad 
selectors for microbial resistance, although it has a 
convincing mechanistic simplicity, has never been docu- 
mented. Bacteria resistant to an antibiotic (naturally or 
by an acquired mechanism) are normally selected by 
the agent or by another agent with a similar spectrum 
or a similar mechanism of resistance. Recent studies 
indicate that the emergence of resistance genes, their 
prevalence in one or more species and their spread 
(clonally, or as genes) are distinct phenomena. These 
are complex problems in which many factors are 
involved, such as: the size and the composition of the 
ecological niche considered; the number of species 
and the size of their populations; the quantity of the 
selecting agents (antibiotics and other antimicrobials); 
the duration of the selection pressure; the pre-existence 
of low level resistant microorganisms able to survive the 
concentrations of antibiotics present in the niche; the 
time of observation; and so on. The ability to select 
resistant organisms is not related to the breadth of the 
bacterial spectrum of an antibiotic. It is related to the 
mechanisms of resistance to that particular antibiotic 
and to several other factors already mentioned. 
The term narrow-spectrum agent is sometimes 
considered to be a synonym of targeted-microorganism 
therapy and an indicator of a physician’s competence 
and concern for ecology. As focused a diagnosis of 
an infection as possible must direct the therapeutic 
decision to the most appropriate conipound(s). The 
appropriate treatment(s) of an infection are those 
that have been proven to cure patients with similar 
infections. The appropriate antibiotic treatment is 
never defined by its antibacterial spectrum. Who 
cares about the spectrum when chloramphenicol or 
ceftriaxone is prescribed to cure enteric fever? 
I should like finally to call attention to many 
guidelines where, without adequate explanation or for 
